KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Common Equity (2016 - 2025)

Historic Common Equity for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $18.7 billion.

  • Vertex Pharmaceuticals' Common Equity rose 1374.93% to $18.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 billion, marking a year-over-year increase of 1374.93%. This contributed to the annual value of $18.7 billion for FY2025, which is 1374.93% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Common Equity stood at $18.7 billion, which was up 1374.93% from $17.3 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' Common Equity's 5-year high stood at $18.7 billion during Q4 2025, with a 5-year trough of $9.0 billion in Q1 2021.
  • Its 5-year average for Common Equity is $14.3 billion, with a median of $15.1 billion in 2023.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Common Equity skyrocketed by 3897.83% in 2021, and later plummeted by 1105.49% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Common Equity stood at $10.1 billion in 2021, then soared by 37.75% to $13.9 billion in 2022, then rose by 26.36% to $17.6 billion in 2023, then dropped by 6.66% to $16.4 billion in 2024, then rose by 13.75% to $18.7 billion in 2025.
  • Its Common Equity stands at $18.7 billion for Q4 2025, versus $17.3 billion for Q3 2025 and $17.2 billion for Q2 2025.